MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.4000
0.0000
0.00%
After Hours: 0.4051 +0.0051 +1.28% 19:53 02/09 EST
OPEN
0.4100
PREV CLOSE
0.4000
HIGH
0.4100
LOW
0.3800
VOLUME
3.39M
TURNOVER
--
52 WEEK HIGH
1.238
52 WEEK LOW
0.3450
MARKET CAP
148.67M
P/E (TTM)
-0.9033
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SGMO last week (0202-0206)?
Weekly Report · 23h ago
Sangamo Biosciences launches dilutive February 2026 financing
TipRanks · 5d ago
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026
NASDAQ · 5d ago
Sangamo advances Fabry gene therapy with pivotal STAAR data
TipRanks · 6d ago
Sangamo Therapeutics Data From Phase 1/2 STAAR Trial Evaluating Isaralgagene Civaparvovec Shows Positive Mean Annualized Estimated Glomerular Filtration Rate Slope At 52 Weeks
Benzinga · 6d ago
Sangamo Therapeutics Announces Positive Phase 1/2 Data for Fabry Disease Gene Therapy Candidate
Reuters · 6d ago
Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor
Reuters · 6d ago
Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy
Reuters · 6d ago
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.